Eckert & Ziegler Strahlen- und Medizintechnik AG

Regulatory Filings • Jun 23, 2009

News Details

Corporate | 23 June 2009 09:23

Eckert & Ziegler’s associated company IBt Bebig signs contracts about a joint venture in the Russian Federation

Eckert & Ziegler Strahlen- und Medizintechnik AG / Joint Venture

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 23.6.2009 - Belgian International Brachytherapy S.A. (IBt Bebig),
an associated company of Eckert & Ziegler AG (ISIN DE0005659700), the
Russian State Fund Corporation Rusnanotech Corp. and the marketing company
Santis Ltd. agreed on the construction of a new production site in the
Russian Federation. 'NanoBrachyTech', holding a minority share of 15% at
IBt Bebig, is supposed to produce mainly medical products for the treatment
of prostate cancer for customers in Russia, Ukraine, Byelorussia, an
Kazakhstan, starting in 2011. The modern necessary production facilities
and the know-how for the manufacturing will be provided by IBt within the
framework of a delivery and licence contract. Some 10 million EUR of
additional turnover as well as a considerable contribution to operating
income resulting from these deliveries and the respective licence payments
are expected within the next two years alone.

'The Russian State Fund's decision in favour of IBt Bebig again confirms
that in our trade a company's size and market share have a considerable
effect on the strategic choice of partners', Andreas Eckert, CEO of Eckert
& Ziegler AG, explained. 'Therefore it was right to create a large European
brachytherapy specialist in early 2008 by bringing our 100% subsidiary
company Bebig GmbH into our then competitor IBt, being attractive also to
financially strong partners outside the European Union. Despite of the
judicial conflict over the takeover offer, we are therefore convinced that
with IBt Bebig we have a jewel with a considerable potential for
development in the coming years. The additional profits from the turnovers
from the facility and the licence fees by IBt Bebig will surely also
provide a noticeable contribution to operating income for Eckert & Ziegler
AG. By now, the market volume for weak radioactive implants in the Russian
Federation may be only 3 million EUR but the growth rates are remarkable.'

On Eckert & Ziegler

Eckert & Ziegler Strahlen- und Medizintechnik AG is a global isotope
technology company and holding company for a number of specialized
subsidiary companies in the field of processing of radioisotopes and of
development, production, and marketing of isotope technology components,
medical devices, and similar products. The group expects a turnover of ca.
100 million EUR for 2009 and is one of the largest suppliers of radioactive
components for radiation therapy and nuclear medicine, employing 520
employees worldwide.

On Rusnanotech

The major partner in the joint venture with IBt Bebig is the Russian
company for nano technologies Rusnanotech, a State Fund with a capital of
more than 5 billion US$. The company co-finances projects characterized by
a large commercial or social benefit for the Russian Federation. On the
basis of long-term success plans by leading Russian and international
experts, Rusnanotech chooses and supports only the most competitive
products. The fund organizes the scientific, technical, and financial
analysis of the projects, participates by means of long-term investments,
and supports its participations with a maximum financial and administrative
effort.

On IBt Bebig

IBt Bebig develops, produces, and sells radiation-technology products for
the treatment of cancer, in particular prostate cancer, worldwide. The
company with its approx. 150 employees is market leader in Europe for weak
radioactive prostate cancer implants. The company's head office is in
Brussels, the main production site is in Berlin. Eckert & Ziegler holds
almost 40% of the economic shares of the company and 29.9% of the voting
rights in the annual general meeting. Eckert & Ziegler owns an option for
another 21% of the annual general meeting's voting rights.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Phone.: +49 (0) 30 / 94 10 84-138, Fax -112
E-mail: karolin.riehle@ezag.de, www.ezag.com

23.06.2009 Financial News transmitted by DGAP

Language: English
Issuer: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084138
Fax: 49 30 941084112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, ISIN DE0005659700
WKN: 565970, ISIN DE000A0L1L69
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf

End of News DGAP News-Service

---